Mesoblast Limited Financial Year End Results: Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

August 26, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Melbourne, Aug 26, 2010 (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today reported its results for the year ended 30 June 2010.

Twitter
LinkedIn
Facebook
Email
Print

Earnings Asia Australia